Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amlodipine/indapamide/telmisartan - George Medicines

Drug Profile

Amlodipine/indapamide/telmisartan - George Medicines

Alternative Names: GMRx2; Indapamide/amlodipine/telmisartan - George Medicines; Telmisartan/amlodipine/indapamide - George Medicines

Latest Information Update: 06 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator George Medicines
  • Class Antihypertensives; Benzimidazoles; Benzoates; Dihydropyridines; Indoles; Ischaemic heart disorder therapies; Small molecules; Sulfonamides
  • Mechanism of Action ACE inhibitors; Angiotensin type 1 receptor antagonists; Calcium channel antagonists; Thiazide-like diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Hypertension

Most Recent Events

  • 29 Apr 2024 George Medicines plans to submit a New Drug Application (NDA) for amlodipine/indapamide/telmisartan for Hypertension, later in 2024
  • 18 Oct 2023 George Medicines completes the phase III GMRx2_PCT trial in Hypertension in USA, Australia, Nigeria, Sri Lanka, and United Kingdom (NCT04518306)
  • 01 Sep 2023 George Medicines completes a phase III trial in Hypertension in Australia, Czech Republic, New Zealand, Poland, Sri Lanka, United Kingdom, and in the US (PO) (NCT04518293)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top